<DOC>
	<DOCNO>NCT00123955</DOCNO>
	<brief_summary>The purpose study examine whether spironolactone improve exercise tolerance quality life elderly patient heart failure preserve ejection fraction ( HFPEF ) .</brief_summary>
	<brief_title>PIE II : Pharmacological Intervention Elderly II</brief_title>
	<detailed_description>Exercise intolerance due HFPEF major cause disability among old Americans . Several line evidence suggest aldosterone antagonism may improve exercise tolerance HFPEF . Therefore , primary aim study test hypothesis spironolactone improve exercise tolerance quality life elderly patient isolate HFPEF . A total 72 participant age 60 old randomize receive either spironolactone 25mg daily placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Ambulatory Medically stable Ages 60 old Diagnosis diastolic heart failure Valvular heart disease Significant change cardiac medication within past 4 week Uncontrolled hypertension Recent debilitate stroke Cancer noncardiovascular condition life expectancy le 2 year Anemia Elevated serum potassium Renal insufficiency Psychiatric disease ( uncontrolled major psychosis , depression , dementia , personality disorder ) Allergy spironolactone ; currently take spironolactone aldosterone antagonist Plans leave area within 1 year Refuses inform consent Failure pas screening test : pulmonary function , echocardiogram , exercise Contraindications magnetic resonance image [ MRI ] ( indwell metalcontaining prosthesis ; pacemaker defibrillator ; history weld occupation ; uncontrollable claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>